Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Leases Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Plus Therapeutics (PSTV) Other Accumulated Expenses (2016 - 2025)

Plus Therapeutics has reported Other Accumulated Expenses over the past 12 years, most recently at $935000.0 for Q4 2025.

Quarterly Other Accumulated Expenses changed N/A to $935000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $935000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $935000.0 for FY2025, N/A changed from the prior year.
Other Accumulated Expenses was $935000.0 for Q4 2025 at Plus Therapeutics, up from $122000.0 in the prior quarter.
Over five years, Other Accumulated Expenses peaked at $935000.0 in Q4 2025 and troughed at $122000.0 in Q4 2021.